Pre-Approval Brand Building: How Biotech Teams are Creating Equity Before Day One

For a biotech preparing to launch, every dollar feels like it belongs in the clinical trial. The science has to work. The data has to land. Approval has to come through. Everything else, including brand, can wait.

That instinct is what costs companies the launch.

Industry data is consistent on the point. Deloitte has found that around 70% of products that miss expectations at launch continue to miss them in subsequent years, while 80% of products that meet or beat expectations continue to do so. The trajectory of a launch gets set early, and it tends to hold. Guidehouse’s analysis of recent biotech launches found that companies investing 18 to 24 months in pre-launch market development achieved roughly 40% higher peak sales on average. McKinsey’s research on first-time biotech launchers shows that the ones who exceed expectations are disproportionately the ones who chose white-space indications and prepared the market accordingly.

The pattern is clear. The biotechs winning at launch are the ones who started building brand equity long before Day One.

Why pre-approval brand building has become non-negotiable

According to IQVIA, emerging biopharma companies now represent 72% of the total drug development pipeline, with that share climbing to 78% in cell and gene therapies. The competitive context for a biotech launch has shifted. A small company is no longer the exception in a category dominated by big pharma. It is increasingly the norm, and it is launching into a market crowded with other small companies doing the same thing.

That changes the math on pre-approval investment. When the entire category is being shaped by emerging companies, the brand that arrives at approval already known to its audience is the one that gets the meeting, gets the formulary review, gets the trial. The brand that arrives unknown is starting a race that other people have been running for a year.

There is also a structural reason it matters now more than it used to. Healthcare practitioners and payers have less time, more options, and higher evidence expectations than they did even five years ago. Approval is no longer the moment a brand introduces itself. By approval, the work of building a relationship with the prescribing audience should already be most of the way done.

What pre-approval brand building actually looks like

Done well, pre-approval brand work is not advertising. The right way to think about it is as foundational identity, scientific credibility, and audience education, executed within every regulatory boundary that applies pre-approval. Three areas matter most.

Corporate identity and brand architecture, established early

The corporate brand is the first thing the world meets. For a pre-commercial biotech, it shows up in investor decks, on conference stages, in publication bylines, and across LinkedIn long before any therapy is approved. That identity needs to be intentional from the start. The companies that arrive at launch with a vague visual system, an inconsistent voice, and a corporate story that has been rewritten three times are starting their commercial life having already taught their audience to expect inconsistency. The companies that arrive with a clear identity, a coherent point of view, and a brand architecture that anticipates the eventual product brand inside it walk into launch with months of audience familiarity already in the bank.

Brand architecture decisions made pre-approval also save real money post-approval. Companies that wait until late in development to decide how their portfolio will be organized, how their products will relate to the corporate parent, and how the eventual product brand will fit alongside the science end up spending launch dollars on rework instead of reach.

Disease state education that earns the audience before the brand asks for it

In any therapeutic area where the science is new or the unmet need is poorly understood, the brand cannot show up at approval expecting HCPs to know why the category matters. The market has to be built. Disease state education is the work of doing that.

Done with rigor, disease state education is not promotional. The content is genuine clinical, scientific, and patient-experience material that helps the eventual prescribing audience understand the disease as well as the company understands it. The cumulative effect, over time, is that the company becomes the most credible source on the condition the therapy is being developed for. By the time approval comes, the audience has been learning from the company for one, two, sometimes three years. They have read the publications, attended the symposia, downloaded the resources, and started to think of the company as the authority in the space.

That earned authority is what brand equity actually is, pre-approval.

Unbranded HCP awareness that primes the relationship without crossing the line

Unbranded work sits in the most regulated and most misunderstood corner of pre-approval marketing. Done badly, it reads as a thinly disguised promotion that compliance will never allow to ship. Done well, it is one of the highest-impact investments a biotech can make in the eighteen months before launch.

Effective unbranded HCP awareness identifies the audience that will eventually prescribe, finds the questions they are already asking about the disease, and answers those questions with the rigor and clarity of a company that takes their time seriously. It builds recognition for the company name. It establishes the company’s voice. It introduces the scientific platform without naming a product. And it does all of that in full compliance with pre-approval promotional regulations.

The biotechs that get this right walk into approval with HCPs who already recognize the company, already trust its science, and already understand the patient problem the therapy is built to solve.

The biotechs that get to Day One already known

Pre-approval brand building is the work of arriving at launch with a head start instead of a starting line. The science is the asset. Pre-approval brand work is the system that makes sure the science actually gets heard.

The biotechs investing this way today are the ones whose launches will look effortless three years from now. They will not be effortless. They will be the result of eighteen, twenty-four, thirty-six months of disciplined work done before Day One.

If your team is in the eighteen-month window before launch and wondering what pre-approval brand investment should actually look like for your therapy, that is a conversation we would welcome.